clinical trial · NCT06948955
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Gastrointestinal Neoplasms, Gastrointestinal Stromal TumorsBezuclastinibSunitinib
brief summary
The purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no comparable or satisfactory alternative therapy options. The combination of bezuclastinib and sunitinib provides broad inhibition of all primary and secondary KIT mutations that commonly occur in GIST.
started
—
primary completion
—
completion
—
last updated
Apr 2, 2026
official title
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol